{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:19:26Z","timestamp":1786735166659,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T00:00:00Z","timestamp":1716854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s12325-024-02883-0","type":"journal-article","created":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T22:02:29Z","timestamp":1716933749000},"page":"2576-2585","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["BRAFV600E Metastatic Melanoma Journey: A Perspective from a Patient and his Oncologist"],"prefix":"10.1007","volume":"41","author":[{"given":"Carsten","family":"Finke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6591-7570","authenticated-orcid":false,"given":"Peter","family":"Mohr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,28]]},"reference":[{"key":"2883_CR1","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1080\/15384047.2019.1640032","volume":"20","author":"LE Davis","year":"2019","unstructured":"Davis LE, Shalin SC, Tackett AJ. Current state of melanoma diagnosis and treatment. Cancer Biol Ther. 2019;20:1366\u201379.","journal-title":"Cancer Biol Ther"},{"key":"2883_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/1479-5876-10-85","volume":"10","author":"PA Ascierto","year":"2012","unstructured":"Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med. 2012;10:85.","journal-title":"J Transl Med"},{"key":"2883_CR3","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.ejca.2022.04.018","volume":"170","author":"C Garbe","year":"2022","unstructured":"Garbe C, Amaral T, Peris K, et al. European consensus-based interdisciplinary guideline for melanoma. part 2: treatment-Update 2022. Eur J Cancer. 2022;170:256\u201384.","journal-title":"Eur J Cancer"},{"key":"2883_CR4","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1007\/s00393-020-00870-8","volume":"79","author":"C Lamos","year":"2020","unstructured":"Lamos C, Hunger RE. Checkpoint inhibitors-indications and application in melanoma patients [in German]. Z Rheumatol. 2020;79:818\u201325.","journal-title":"Z Rheumatol"},{"key":"2883_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jid.2020.03.943","volume":"141","author":"RW Jenkins","year":"2021","unstructured":"Jenkins RW, Fisher DE. Treatment of advanced melanoma in 2020 and beyond. J Invest Dermatol. 2021;141:23\u201331.","journal-title":"J Invest Dermatol"},{"key":"2883_CR6","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N Engl J Med. 2019;381:1535\u201346.","journal-title":"N Engl J Med"},{"key":"2883_CR7","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/S1470-2045(19)30388-2","volume":"20","author":"C Robert","year":"2019","unstructured":"Robert C, Ribas A, Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u201351.","journal-title":"Lancet Oncol"},{"key":"2883_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30:582\u20138.","journal-title":"Ann Oncol"},{"key":"2883_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1097\/CCO.0000000000000426","volume":"30","author":"P Koelblinger","year":"2018","unstructured":"Koelblinger P, Thuerigen O, Dummer R. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 2018;30:125\u201333.","journal-title":"Curr Opin Oncol"},{"key":"2883_CR10","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S0140-6736(96)91208-8","volume":"347","author":"LH Goldberg","year":"1996","unstructured":"Goldberg LH. Basal cell carcinoma. Lancet. 1996;347:663\u20137.","journal-title":"Lancet"},{"key":"2883_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2478\/v10019-010-0008-x","volume":"44","author":"P Strojan","year":"2010","unstructured":"Strojan P. Role of radiotherapy in melanoma management. Radiol Oncol. 2010;44:1\u201312.","journal-title":"Radiol Oncol"},{"key":"2883_CR12","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1016\/S0033-8389(05)70027-0","volume":"36","author":"MR Paley","year":"1998","unstructured":"Paley MR, Ros PR. Hepatic metastases. Radiol Clin North Am. 1998;36:349\u201363.","journal-title":"Radiol Clin North Am"},{"key":"2883_CR13","first-page":"81","volume":"2","author":"PM Kaufmann","year":"1992","unstructured":"Kaufmann PM, Crone-Munzebrock W. Tumor follow-up using sonography and computed tomography in the abdominal region of patients with malignant melanoma [in German]. Aktuelle Radiol. 1992;2:81\u20135.","journal-title":"Aktuelle Radiol"},{"key":"2883_CR14","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/PPO.0b013e31824f11bf","volume":"18","author":"MA Wilson","year":"2012","unstructured":"Wilson MA, Nathanson KL. Molecular testing in melanoma. Cancer J. 2012;18:117\u201323.","journal-title":"Cancer J"},{"key":"2883_CR15","doi-asserted-by":"publisher","first-page":"9506","DOI":"10.1200\/JCO.2016.34.15_suppl.9506","volume":"34","author":"GV Long","year":"2016","unstructured":"Long GV, Atkinson V, Cebon JS, et al. Pembrolizumab (pembro) plus ipilimumab (ipi) for advanced melanoma: results of the KEYNOTE-029 expansion cohort [ASCO abstract 9506]. J Clin Oncol. 2016;34:9506.","journal-title":"J Clin Oncol"},{"key":"2883_CR16","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161:205\u201314.","journal-title":"Cell"},{"key":"2883_CR17","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376:1015\u201326.","journal-title":"N Engl J Med"},{"key":"2883_CR18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334.","journal-title":"N Engl J Med"},{"key":"2883_CR19","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","volume":"18","author":"P Sharma","year":"2017","unstructured":"Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312\u201322.","journal-title":"Lancet Oncol"},{"key":"2883_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1053\/j.seminoncol.2017.06.002","volume":"44","author":"P Fessas","year":"2017","unstructured":"Fessas P, Lee H, Ikemizu S, Janowitz T. A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. Semin Oncol. 2017;44:136\u201340.","journal-title":"Semin Oncol"},{"key":"2883_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2023.100193","volume":"6","author":"X Sun","year":"2023","unstructured":"Sun X, Mei X, Liu Y. Exacerbation of psoriasis induced by nivolumab in a patient with stage IIIc gastric adenocarcinoma: a case report and literature review. J Transl Autoimmun. 2023;6: 100193.","journal-title":"J Transl Autoimmun"},{"key":"2883_CR22","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","volume":"390","author":"J Schachter","year":"2017","unstructured":"Schachter J, Ribas A, Long GV, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Lancet. 2017;390:1853\u201362.","journal-title":"Lancet"},{"key":"2883_CR23","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","volume":"19","author":"R Dummer","year":"2018","unstructured":"Dummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315\u201327.","journal-title":"Lancet Oncol"},{"key":"2883_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.2217\/fon-2022-1258","volume":"19","author":"R Dummer","year":"2023","unstructured":"Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF. Future Oncol. 2023;19:1091\u20138.","journal-title":"Future Oncol"},{"key":"2883_CR25","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.2217\/fon-2023-0414","volume":"19","author":"AC van Akkooi","year":"2023","unstructured":"van Akkooi AC, Hauschild A, Long GV, et al. COLUMBUS-AD: phase III study of adjuvant encorafenib + binimetinib in resected stage IIB\/IIC BRAF V600-mutated melanoma. Future Oncol. 2023;19:2017\u201327.","journal-title":"Future Oncol"},{"key":"2883_CR26","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.3390\/cancers12071823","volume":"12","author":"I Proietti","year":"2020","unstructured":"Proietti I, Skroza N, Michelini S, et al. BRAF inhibitors: molecular targeting and immunomodulatory actions. Cancers (Basel). 2020;12:1823.","journal-title":"Cancers (Basel)"},{"key":"2883_CR27","doi-asserted-by":"publisher","first-page":"4621","DOI":"10.1200\/JCO.22.02322","volume":"41","author":"PA Ascierto","year":"2023","unstructured":"Ascierto PA, Dummer R, Gogas HJ, et al. Contribution of MEK inhibition to BRAF\/MEK inhibitor combination treatment of BRAF-mutant melanoma: part 2 of the randomized, open-label, phase III COLUMBUS trial. J Clin Oncol. 2023;41:4621\u201331.","journal-title":"J Clin Oncol"},{"key":"2883_CR28","first-page":"5036213","volume":"2018","author":"I Russo","year":"2018","unstructured":"Russo I, Zorzetto L, Chiarion Sileni V, Alaibac M. Cutaneous side effects of targeted therapy and immunotherapy for advanced melanoma. Scientifica (Cairo). 2018;2018:5036213.","journal-title":"Scientifica (Cairo)"},{"key":"2883_CR29","unstructured":"Array BioPharma Inc. BRAFTOVI\u00ae (encorafenib) prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12990. Accessed 12 Feb 2024."},{"key":"2883_CR30","unstructured":"Array BioPharma Inc. MEKTOVI\u00ae (binimetinib) prescribing information. 2023. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=12988. Accessed 12 Feb 2024."},{"key":"2883_CR31","doi-asserted-by":"publisher","first-page":"4178","DOI":"10.1200\/JCO.21.02659","volume":"40","author":"R Dummer","year":"2022","unstructured":"Dummer R, Flaherty KT, Robert C, et al. COLUMBUS 5-year update: a randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma. J Clin Oncol. 2022;40:4178\u201388.","journal-title":"J Clin Oncol"},{"key":"2883_CR32","doi-asserted-by":"publisher","first-page":"S1707","DOI":"10.1016\/j.annonc.2023.10.317","volume":"34","author":"AM Haydon","year":"2023","unstructured":"Haydon AM, Schadendorf D, Dummer R, et al. 602P COLUMBUS 7-year update: a randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma. Ann Oncol. 2023;34:S1707\u20138.","journal-title":"Ann Oncol"},{"key":"2883_CR33","doi-asserted-by":"crossref","unstructured":"Schulz A, Raetz J, Karitzky PC et al. Head-to-head comparison of BRAF\/MEK inhibitor combinations proposes superiority of encorafenib plus trametinib in melanoma. Cancers (Basel). 2022;14:4930.","DOI":"10.3390\/cancers14194930"},{"key":"2883_CR34","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1002\/cncr.30444","volume":"123","author":"EH Byrne","year":"2017","unstructured":"Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123:2143\u201353.","journal-title":"Cancer"},{"key":"2883_CR35","doi-asserted-by":"publisher","first-page":"731","DOI":"10.2105\/AJPH.2020.305567","volume":"110","author":"J Berk-Krauss","year":"2020","unstructured":"Berk-Krauss J, Stein JA, Weber J, Polsky D, Geller AC. New systematic therapies and trends in cutaneous melanoma deaths among US whites, 1986\u20132016. Am J Public Health. 2020;110:731\u20133.","journal-title":"Am J Public Health"},{"key":"2883_CR36","doi-asserted-by":"publisher","first-page":"636","DOI":"10.3390\/vaccines11030636","volume":"11","author":"D Bafaloukos","year":"2023","unstructured":"Bafaloukos D, Gazouli I, Koutserimpas C, Samonis G. Evolution and progress of mRNA vaccines in the treatment of melanoma: future prospects. Vaccines (Basel). 2023;11:636.","journal-title":"Vaccines (Basel)"},{"key":"2883_CR37","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1097\/CCO.0000000000000922","volume":"35","author":"EB Ellingsen","year":"2023","unstructured":"Ellingsen EB, Bjorheim J, Gaudernack G. Therapeutic cancer vaccination against telomerase: clinical developments in melanoma. Curr Opin Oncol. 2023;35:100\u20136.","journal-title":"Curr Opin Oncol"},{"key":"2883_CR38","first-page":"1278","volume":"13","author":"mRNA Vaccine Slows Melanoma Recurrence","year":"2023","unstructured":"mRNA Vaccine Slows Melanoma Recurrence. Cancer Discov. 2023;13:1278.","journal-title":"Cancer Discov"},{"key":"2883_CR39","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/CCO.0000000000000923","volume":"35","author":"AM D'Alise","year":"2023","unstructured":"D\u2019Alise AM, Scarselli E. Getting personal in metastatic melanoma: neoantigen-based vaccines as a new therapeutic strategy. Curr Opin Oncol. 2023;35:94\u20139.","journal-title":"Curr Opin Oncol"},{"key":"2883_CR40","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1158\/1078-0432.CCR-11-2479","volume":"18","author":"JS Wilmott","year":"2012","unstructured":"Wilmott JS, Long GV, Howle JR, et al. Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma. Clin Cancer Res. 2012;18:1386\u201394.","journal-title":"Clin Cancer Res"},{"key":"2883_CR41","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s10555-023-10097-z","volume":"42","author":"M Haist","year":"2023","unstructured":"Haist M, Stege H, Kuske M, et al. Combination of immune-checkpoint inhibitors and targeted therapies for melanoma therapy: the more, the better? Cancer Metastasis Rev. 2023;42:481\u2013505.","journal-title":"Cancer Metastasis Rev"},{"key":"2883_CR42","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1111\/phpp.12770","volume":"38","author":"L Ding","year":"2022","unstructured":"Ding L, Gosh A, Lee DJ, et al. Prognostic biomarkers of cutaneous melanoma. Photodermatol Photoimmunol Photomed. 2022;38:418\u201334.","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"2883_CR43","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.ccell.2020.10.001","volume":"39","author":"DL Jardim","year":"2021","unstructured":"Jardim DL, Goodman A, de Melo GD, Kurzrock R. The challenges of tumor mutational burden as an immunotherapy biomarker. Cancer Cell. 2021;39:154\u201373.","journal-title":"Cancer Cell"},{"key":"2883_CR44","doi-asserted-by":"publisher","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","volume":"29","author":"T Carvalho","year":"2023","unstructured":"Carvalho T. Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial. Nat Med. 2023;29:2379\u201380.","journal-title":"Nat Med"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02883-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02883-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,28]],"date-time":"2024-06-28T10:40:44Z","timestamp":1719571244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02883-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,28]]},"references-count":44,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["2883"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02883-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,28]]},"assertion":[{"value":"14 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. med. Peter Mohr has received payments or honoraria from MSD Pharma GmbH, Novartis, Bristol Myers Squibb, Pierre Fabre, Sanofi-Genzyme, Roche Pharma AG, Beiersdorf AG, Amgen, Almirall Hermal GmbH, Sun Pharma, and Regeneron Pharmaceuticals; support for attending meetings and\/or travel from MSD, Bristol Myers Squibb, Pierre Fabre, Sun Pharma and Regeneron; and he has held unpaid leadership or fiduciary roles in MID Melanom Info Deutschland, as well as HKND Hautkrebs Netzwerk Deutschland. He is affiliated to the Clinique of Dermatology, Buxtehude, Germany. Carsten Finke has nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors. Carsten Finke provided written informed consent for identifying his personal data in this case report.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}